Ipamorelin: Dosing Protocols

Research Dosing Disclaimer#

The dosing information below is derived from research studies and is provided for educational purposes only. Ipamorelin is not approved for human use, and no official dosing guidelines exist.

Dose-Response Data#

We identified dose–response evidence for ipamorelin primarily in rats with post‑operative ileus (POI), supplemented by mouse and swine data, and qualitative reports of bone outcomes in rats. The clearest quantitative dose–response findings are from repetitive, body‑weight–adjusted intravenous dosing in rats.

Key animal dose–response findings

• Rat, POI model, intravenous bolus dosing via jugular catheter: Single post‑surgical doses of 0.1–1 mg/kg were tested. A single 1 mg/kg dose shortened time to first bowel movement, but single‑dose regimens did not significantly increase cumulative fecal output or food intake over 48 h (n≈9–12 per group). In a repetitive dosing paradigm designed around a ~2 h half‑life, rats received 0.01, 0.1, or 1 mg/kg as two series of four bolus infusions/day at 3‑h intervals for 48 h. Repetitive dosing at 0.1 and 1 mg/kg increased cumulative fecal pellet output and cumulative food intake, with regression slopes higher than vehicle; 1 mg/kg also increased 48‑h body‑weight gain (n=8–9 per group). A comparator, GHRP‑6 20 µg/kg i.v., also accelerated colonic transit. Thus, for GI motility and feeding recovery, the dose–response favored repeated 0.1–1 mg/kg i.v. over single dosing.

• Mouse, twice‑daily subcutaneous ipamorelin 250 µg/kg for 9 weeks: In GH‑deficient and GH‑intact mice, ipamorelin produced modest body‑weight increases compared with larger gains from recombinant GH (1.75 mg/kg), indicating anabolic effects but a smaller magnitude than GH at the tested doses.

• Rat, bone outcomes (qualitative dose reporting not available in retrieved excerpts): Reviews summarizing primary rat studies report that ipamorelin increased longitudinal bone growth rates after 15 days and increased tibial and vertebral bone mineral content after 12 weeks in young female Sprague–Dawley rats; cotreatment with glucocorticoid, ipamorelin prevented glucocorticoid‑induced decreases in bone formation and muscle atrophy. However, explicit mg/kg or µg/kg dosing and routes were not provided in the available excerpts (likely subcutaneous in the bone studies).

• Swine, PK/PD and endocrine selectivity: Reviews report intravenous and subcutaneous administration with a single GH peak approximately 0.67 h after dosing, a terminal half‑life ~2 h, weight‑normalized clearance ~0.078 L/h/kg, and selective GH elevation without ACTH/cortisol increases; explicit mg/kg dosing was not extractable from the provided text.

Embedded summary table of animal dose–response data is provided below.

Interpretation

• In rats with POI, repeated i.v. ipamorelin at 0.1–1 mg/kg (normalized by body weight) produced dose‑responsive improvements in GI transit recovery, fecal output, food intake, and short‑term body‑weight gain; single i.v. dosing was insufficient for sustained effects on fecal output and intake. This supports a regimen‑dependent dose–response where higher repeated doses confer greater effects on GI endpoints.
• In mice, chronic s.c. 250 µg/kg twice‑daily produced modest anabolic/weight effects versus GH, consistent with weaker growth promotion at that dose relative to pharmacologic GH dosing.
• Bone endpoints in rats show favorable effects qualitatively, but the lack of explicit dosing in the retrieved excerpts limits quantitative dose–response interpretation; the studies nonetheless suggest ipamorelin can increase longitudinal growth and BMC and mitigate glucocorticoid‑induced suppression of bone formation.

Limitations

• For rat bone and glucocorticoid‑rescue studies and swine endocrine studies, specific mg/kg doses and, in some cases, routes were not present in the provided text. Our quantitative dose–response conclusions therefore rely chiefly on the rat POI model with explicit 0.01–1 mg/kg i.v. dosing.

Administration Routes#

Summary. Quantitative human pharmacokinetics are published for intravenous ipamorelin and serve as the reference. For subcutaneous administration, the route is documented but human bioavailability and full PK parameters have not been disclosed; available preclinical work and class knowledge suggest a short elimination half‑life and rapid onset relative to oral or topical. Oral bioavailability of peptidyl GHSs like ipamorelin is reported to be very low (often <1%), and medicinal chemistry efforts around the ipamorelin/NN703 series did not yield sufficient oral exposure; no oral PK for native ipamorelin has been reported. Intramuscular and topical/transdermal pharmacokinetics for ipamorelin are not documented in the literature retrieved here. These findings and gaps are consolidated below.

Route‑by‑route comparison

IV (reference). In humans, after IV administration, ipamorelin shows a terminal half‑life of about 2 h, clearance ~0.078 L/h/kg, and steady‑state volume of distribution ~0.22 L/kg; a single growth hormone (GH) peak occurs at ~0.67 h, reflecting pharmacodynamic response to systemic exposure (these PD timings are not a Cmax surrogate for ipamorelin itself). These parameters set the benchmark for systemic exposure and disposition.

Subcutaneous (SC). Reviews list SC as a clinical route for ipamorelin, but quantitative human SC Cmax, Tmax, AUC, or absolute bioavailability (F) are not reported in the sources identified. Preclinical dosing paradigms for ipamorelin in rodents adopted multiple boluses per day explicitly because of a relatively short half‑life on the order of ~2 h, consistent with rapid systemic clearance after parenteral dosing. In the absence of human SC PK, the expected qualitative differences versus IV are lower Cmax, delayed Tmax, and reduced absolute exposure depending on site absorption and peptide proteolysis; however, the magnitude for ipamorelin specifically remains unpublished in the evidence located here.

Intramuscular (IM). No primary human or animal PK/bioavailability data for ipamorelin given IM were found in the retrieved literature. Therefore, route‑specific values (Cmax, Tmax, F) cannot be stated. Any extrapolation from SC/IV would be speculative without study.

Oral (PO). Peptidyl growth hormone secretagogues (GHSs) generally have negligible oral bioavailability in humans (reported F <1% for peptide GHSs), necessitating intranasal or subcutaneous delivery to achieve exposure. Within the Novo Nordisk series related to NN703/tabimorelin and hybrids with ipamorelin features, medicinal chemistry reports explicitly note that compounds evaluated “were not sufficiently orally bioavailable” to progress (cutoff discussed as fPO >20%), underscoring the challenge for this chemotype; no quantitative oral PK for native ipamorelin itself is reported. A metabolism/doping‑control study notes that GHRPs can be administered by several routes and have variable bioavailability, but does not provide quantitative oral F for ipamorelin. Together, these data support the conclusion that native ipamorelin has very low or negligible oral bioavailability without enabling technologies.

Topical/transdermal. No published PK or bioavailability data for topical/transdermal ipamorelin were identified. General peptide ADME principles indicate low passive skin permeability and susceptibility to proteolysis, making transdermal delivery of linear peptides unlikely without specialized systems (e.g., iontophoresis, microneedles, permeation enhancers). The GHRP metabolism review enumerates multiple non‑oral routes used for this class (IV, SC, intranasal, buccal) but does not provide evidence for topical ipamorelin. Accordingly, topical/transdermal ipamorelin remains unsupported by the available evidence.

Context from clinical development and class. Ipamorelin advanced to Phase 2 for postoperative ileus but development was discontinued for lack of efficacy; available reviews summarize route listings (including IV and SC) and outcomes but do not add route‑specific PK or bioavailability beyond the IV human dataset. Across peptide therapeutics more broadly, short half‑life and low oral bioavailability are common development constraints, aligning with the observations here.

• Highest‑quality quantitative PK exists for IV ipamorelin in humans (t1/2 ≈ 2 h; CL ≈ 0.078 L/h/kg; Vss ≈ 0.22 L/kg; GH peak ~0.67 h), and these values anchor systemic disposition expectations.
• SC delivery is feasible and used in the class; for ipamorelin, published human SC bioavailability and PK parameters were not identified. Preclinical and class data imply rapid absorption with short t1/2 similar to IV, but the absolute F remains unknown publicly.
• IM PK for ipamorelin is not documented in the retrieved sources.
• Oral delivery of native ipamorelin is not supported due to very low bioavailability typical for peptidyl GHSs (often <1%) and unsuccessful attempts to achieve sufficient oral exposure in related series; no oral PK for ipamorelin itself was found.
• Topical/transdermal delivery lacks published evidence and is unlikely to yield systemic exposure without specialized delivery technologies given peptide physicochemistry.

Evidence limitations. Where route‑specific ipamorelin data were unavailable (SC absolute F, IM PK, topical/transdermal), conclusions are constrained to documented route listings or class‑level pharmacology and peptide ADME principles. Additional dedicated human PK studies would be required to quantify SC and IM bioavailability and to assess any specialized noninvasive delivery approaches.

Human-Equivalent Dosing#

Allometric methods used in the literature and their applicability to ipamorelin. When ipamorelin-specific scaling is not reported, standard approaches cited in guidance and reviews are applicable to peptide agonists:

• Body surface area (BSA)/Km-based HED and exponent-based allometry. FDA-style HED scaling expresses HED as Animal dose × (W_animal/W_human)^(1−b), with typical allometric exponents b≈0.67 (conservative) or 0.75; these are equivalent to BSA-based conversions using species Km factors. Methodological sources summarize equations, example calculations, and emphasize how exponent choice alters HED. Reviews caution that simple BSA conversions can mislead without PK/PD context. Broader PK allometry literature supports body-weight based allometry over BSA for PK parameter prediction and highlights pitfalls affecting accuracy.
• MABEL and PK-guided approaches. For agonistic biologics, guidance recommends considering minimally anticipated biologic effect level (MABEL) and integrating in vitro/in vivo exposure–response and PK data to choose safe/active starting doses; however, ipamorelin publications located here do not explicitly apply MABEL in dose selection.

Illustrative HED conversions from reported ipamorelin animal doses. Although the ipamorelin papers did not perform allometric conversions, applying standard methods to their rat doses yields the following HED ranges (assuming 0.26 kg rat and 60 kg human):

• Rat IV 0.01–1 mg/kg (Venkova 2009): using b=0.67 (i.e., exponent 1−b=0.33), the mass-ratio factor is ≈(0.26/60)^0.33≈0.166; HED ≈0.00166–0.166 mg/kg. Using BSA/Km tables gives a similar factor for rat→human (~0.162), yielding ≈0.00162–0.162 mg/kg. The human phase 2 clinical dose, 0.03 mg/kg IV BID, lies within this bracket.
• Rat s.c. continuous 0.5 mg/kg/day (Svensson 2000): applying the same exponents produces an HED of ≈0.08 mg/kg/day (0.5×~0.162–0.166), again an illustrative value rather than one stated by the authors.

Summary table of sources, animal doses, and methods appears below.

Conclusions. Ipamorelin preclinical reports in rats do not state explicit animal-to-human dose scaling, and the phase 2 clinical report gives a human dose without describing the conversion. In the absence of ipamorelin-specific conversions, the literature supports applying standard allometric methods: BSA/Km-based HED or exponent allometry with b≈0.67–0.75, optionally supplemented by PK-guided or MABEL considerations. Illustrative conversions of rat ipamorelin doses via these methods span HEDs that include the 0.03 mg/kg IV BID dose used clinically, but method choice and PK/PD context materially affect projections, emphasizing the need to pair any simple HED with pharmacokinetics and pharmacodynamics rather than relying on BSA alone.

Evidence Gaps#

• No human dose-finding studies have been completed
• Allometric scaling from animal models has inherent limitations
• Route-specific bioavailability data in humans is absent
• Optimal treatment duration has not been established

Related Reading#

• Ipamorelin overview and research guide
• Ipamorelin side effects profile
• Ipamorelin research evidence